NOVATO, Calif.--(BUSINESS WIRE)--Biosearch Technologies, Inc. (BTI) announced today it has been granted a worldwide license to the non-coding DNA patents owned by Genetic Technologies Limited, (NASDAQ GM: GENE, ASX: GTG). BTI becomes the first oligonucleotide synthesis company to take a license from GTG to specifically manufacture and distribute oligos, probes and primers for research use only (RUO), under the GTG patents. The GTG license extends to all genomes and includes Single Nucleotide Polymorphism (SNP) genotyping and allelic discrimination. All Biosearch DNA customers will now be covered under the GTG patents with their use of Biosearch’s products for RUO.
